Drug intelligence / Profile preview

NVD200

Development stage: Discontinued
Lead developer: Invivyd
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

**NVD200** is an investigational, two-antibody SARS-CoV-2 combination developed by Invivyd for the prevention and treatment of COVID-19. It comprises the fully human IgG1 monoclonal antibodies VYD222 and VYD224, which bind distinct, non-overlapping epitopes in the receptor-binding domain of the SARS-CoV-2 spike protein. The combination was designed to provide potent and broad viral neutralization, a high barrier to viral escape, and prolonged activity. Invivyd selected NVD200 for clinical advancement in 2022 but subsequently prioritized development of its VYD222 component as a faster path to patients amid changes in the COVID-19 regulatory environment. ([invivyd.com](https://www.invivyd.com/wp-content/uploads/2023/08/ECCMID-2023_NVD200-potently-neutralises-Omicron-and-its-sublineages-_Final-Poster.pdf))

Other names: NVD 200NVD200NVD-200

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on NVD200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVD200.

Explore the full profile